


THEMIS TRIAL

Ticagrelor in Patients With Stable Coronary Disease and Diabetes




Multicenter, randomized, double-blind, placebo-controlled clinical trial



Objective: To assess if adding ticagrelor to aspirin improve outcomes in patients with stable coronary artery disease (CAD) and type 2 diabetes who have not had a myocardial infarction (MI) or stroke.

19,220 patients


Inclusion criteria: patients of age > 50 years who had stable CAD and type 2 diabetes without history of MI or stroke and had not been on dual antiplatelet therapy.



Ticagrelor + aspirin
(n=9,619)



Placebo + aspirin
(n=9,601)



PRIMARY OUTCOME

7.7

CV death, MI, or stroke %
HR 0.90; 95% CI, 0.81 to 0.99; P=0.04

8.5

SECONDARY OUTCOME

3.8

CV death %
HR 1.02; 95% CI, 0.88 to 1.18; P=0.79

3.7

2.2

TIMI major bleeding %
HR 2.32; 95% CI, 1.82 to 2.94; P<0.001

1.0

Conclusion: In patients with stable CAD and diabetes without history of MI or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic CV events but a higher incidence of major bleeding than those who received placebo plus aspirin.